» Articles » PMID: 20009035

Hypercholesterolemia Promotes Bone Marrow Cell Mobilization by Perturbing the SDF-1:CXCR4 Axis

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2009 Dec 17
PMID 20009035
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Hypercholesterolemia is associated with elevated peripheral blood leukocytes and increased platelet levels, generally attributed to cholesterol-induced proinflammatory cytokines. Bone marrow (BM) cell mobilization and platelet production is achieved by disrupting the SDF-1:CXCR4 axis, namely with granulocyte colony-stimulating factor and/or CXCR4 antagonists. Here we show that high cholesterol disrupts the BM SDF-1:CXCR4 axis; promotes the mobilization of B cells, neutrophils, and progenitor cells (HPCs); and creates thrombocytosis. Hypercholesterolemia was achieved after a 30-day high-cholesterol feeding trial, resulting in elevated low-density lipoprotein (LDL) cholesterol levels and inversion of the LDL to high-density lipoprotein cholesterol ratio. Hypercholesterolemic mice displayed lymphocytosis, increased neutrophils, HPCs, and thrombocytosis with a lineage-specific decrease in the BM. Histologic analysis revealed that megakaryocyte numbers remained unaltered but, in high-cholesterol mice, they formed large clusters in contact with BM vessels. In vitro, LDL induced stromal cell-derived factor-1 (SDF-1) production, suggesting that megakaryocyte delocalization resulted from an altered SDF-1 gradient. LDL also stimulated B cells and HPC migration toward SDF-1, which was blocked by scavenger receptor class B type I (cholesterol receptor) inhibition. Accordingly, hypercholesterolemic mice had increased peripheral blood SDF-1 levels, increased platelets, CXCR4-positive B lymphocytes, neutrophils, and HPCs. High cholesterol interferes with the BM SDF-1:CXCR4 axis, resulting in lymphocytosis, thrombocytosis, and HPC mobilization.

Citing Articles

Bone Marrow Niche in Cardiometabolic Disease: Mechanisms and Therapeutic Potential.

Kohutek Z, Caslin H, Fehrenbach D, Heimlich J, Brown J, Madhur M Circ Res. 2025; 136(3):325-353.

PMID: 39883790 PMC: 11790260. DOI: 10.1161/CIRCRESAHA.124.323778.


Lipoprotein metabolism mediates hematopoietic stem cell responses under acute anemic conditions.

Saito K, van der Garde M, Umemoto T, Miharada N, Sjoberg J, Sigurdsson V Nat Commun. 2024; 15(1):8131.

PMID: 39284836 PMC: 11405780. DOI: 10.1038/s41467-024-52509-w.


Immunometabolism in atherosclerotic disorders.

Fleetwood A, Noonan J, La Gruta N, Kallies A, Murphy A Nat Cardiovasc Res. 2024; 3(6):637-650.

PMID: 39196223 DOI: 10.1038/s44161-024-00473-5.


Metabolism and HSC fate: what NADPH is made for.

Morganti C, Bonora M, Ito K Trends Cell Biol. 2024; .

PMID: 39054107 PMC: 11757803. DOI: 10.1016/j.tcb.2024.07.003.


Chemical conjugation mitigates immunotoxicity of chemotherapy via reducing receptor-mediated drug leakage from lipid nanoparticles.

Zheng C, Zhang W, Gong X, Xiong F, Jiang L, Zhou L Sci Adv. 2024; 10(23):eadk9996.

PMID: 38838152 PMC: 11152135. DOI: 10.1126/sciadv.adk9996.